sis. The
Company has two broad platform technologies: dendritic cell-based vaccines,
and therapeutic antibodies. The Company is currently conducting a large
clinical trial in Glioblastoma multiforme, which is designed and powered to
serve as a pivotal trial. The Company has also received clearance from the
FDA for a large Phase III trial in prostate cancer, and clearance from the
FDA for Phase I trials in five other cancers. The Company has started, and
is currently enrolling patients in, a Phase I/II trial with DCVax(R) for
recurrent ovarian cancer. The Company also has a second technology
platform, involving monoclonal antibodies to CXCR4, which is at the late
pre-clinical development stage.
For further information, please visit the company web site at
http://www.nwbio.com.
About the Al Rajhi Group
Al Rajhi Holdings W.L.L. and Al Rajhi Partners (together "Al Rajhi")
represent the business interests of Sheikh Abdulrahman Saleh Al Rajhi and
his immediate family in Saudi Arabia.
Al Rajhi is a private investment company and has investments in
financial services, infrastructure, mining, healthcare, biotechnology, real
estate, oil and gas. Key investments include Bank Al Bilad, DanaGas, Saudi
Telecom, Saudi Cement and Procare hospitals. Khalid al Rajhi, CEO of Al
Rajhi, is a director of each of these companies.
Disclaimer
Statements made in this news release that are not historical facts,
including statements concerning the Company's plans to move its programs
forward, statements regarding the Company's clinical trials and other
business development activities, and statements regarding its fundraising
activities, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as "expects,"
"believes," "intends," and similar expressions are intended to identify
forward-looking statements. Actual results may differ materially fro
'/>"/>
SOURCE Northwest Biotherapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast2.
Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference3.
Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics4.
Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer5.
D-Pharm Secures Funding From Israels Chief Scientists Office6.
Aerovance Secures $20 Million in Debt Financing7.
Amarin Secures Global Intellectual Property Rights for Lipid Programs8.
Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs9.
Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition10.
Taligen Therapeutics Secures Series B Financing11.
Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States